Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Top Cited Papers
Open Access
- 1 February 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 22 (3), 262-269
- https://doi.org/10.1038/nm.4040
Abstract
Drug-tolerant but initially EGFRT790M-negative tumor cells that undergo genetic evolution to acquire resistance to EGFR inhibitors are more resistant than pre-existing EGFRT790M -positive clones to subsequent therapy. Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFRT790M gatekeeper mutation can occur either by selection of pre-existing EGFRT790M-positive clones or via genetic evolution of initially EGFRT790M-negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFRT790M; treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor–resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.Keywords
This publication has 55 references indexed in Scilit:
- Studying clonal dynamics in response to cancer therapy using high-complexity barcodingNature Medicine, 2015
- Acquired resistance to TKIs in solid tumours: learning from lung cancerNature Reviews Clinical Oncology, 2014
- High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact?Journal of Thoracic Oncology, 2013
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005